Compare BIOX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIOX | SKYE |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 20.0M |
| IPO Year | 2019 | 2013 |
| Metric | BIOX | SKYE |
|---|---|---|
| Price | $0.35 | $0.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.33 | ★ $15.00 |
| AVG Volume (30 Days) | 98.7K | ★ 150.0K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.28 |
| 52 Week High | $3.25 | $4.99 |
| Indicator | BIOX | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 37.15 |
| Support Level | $0.31 | N/A |
| Resistance Level | $0.40 | $0.84 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 55.88 | 61.55 |
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.